Published in Br J Pharmacol on November 01, 2001
Triphasic blood pressure responses to cannabinoids: do we understand the mechanism? Br J Pharmacol (2012) 1.00
Influence of the CB(1) receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats. Br J Pharmacol (2002) 0.96
Analysis of the respiratory effects of cannabinoids in rats. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.82
Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. Neuropsychopharmacology (2017) 0.78
Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol (2008) 0.76
Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation. Proc Natl Acad Sci U S A (2016) 0.75
What is the Association of Cannabis Consumption and Cardiovascular Complications? Subst Abuse (2015) 0.75
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett (1994) 5.30
Pharmacology of cannabinoid receptor ligands. Curr Med Chem (1999) 2.34
Cannabinoid pharmacology. Pharmacol Rev (1986) 2.15
Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol (1996) 1.75
Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol (1997) 1.61
Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol (1996) 1.40
Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol (1999) 1.37
Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther (1994) 1.33
Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol (1997) 1.26
Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther (1996) 1.24
Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med (Berl) (1999) 1.14
Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmiedebergs Arch Pharmacol (1997) 1.12
Non-cholinergic component of rat splanchnic nerves predominates at low neuronal activity and is eliminated by naloxone. J Physiol (1987) 1.09
Exocytosis in chromaffin cells of the adrenal medulla. Int Rev Cytol (1998) 1.09
Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther (1993) 1.08
"Real time" measurement of endogenous dopamine release during short trains of pulses in slices of rat neostriatum and nucleus accumbens: role of autoinhibition. Naunyn Schmiedebergs Arch Pharmacol (1991) 1.04
Cardiovascular effects of delta-9-tetrahydrocannabinol in man. Clin Pharmacol Ther (1972) 0.97
Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.94
Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther (2001) 0.92
Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.92
Simultaneous amperometric measurement of ascorbate and catecholamine secretion from individual bovine adrenal medullary cells. Anal Chem (1995) 0.90
Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience (1998) 0.89
Rapid changes in striatal ascorbate in response to tail-pinch monitored by constant potential voltammetry. Neuroscience (1989) 0.85
Desipramine inhibits sympathetic nerve activity in the rabbit. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.82
Effects of acute and subchronic delta 9-tetrahydrocannabinol administration on the plasma catecholamine, beta-endorphin, and corticosterone levels and splenic natural killer cell activity in rats. Proc Soc Exp Biol Med (1985) 0.82
Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol Biochem Behav (1991) 0.81
Effect of delta 9-THC on brain and plasma catecholamine levels as measured by HPLC. Brain Res Bull (1985) 0.80
1 -tetrahydrocannabinol, synhexyl and marijuana extract administered orally in man: catecholamine excretion, plasma cortisol levels and platelet serotonin content. Psychopharmacologia (1970) 0.78
Effect of chronic administration of delta 9-tetrahydrocannabinol on the endogenous opioid peptide and catecholamine levels in the diencephalon and plasma of the rat. Subst Alcohol Actions Misuse (1984) 0.77
Effect of cannabis sativa administered by smoking on biogenic amine excretion in man. Res Commun Chem Pathol Pharmacol (1973) 0.77
Distribution of adrenaline, noradrenaline, acid phosphatase, cholinesterases and non-specific esterases in the adrenal medulla of some mammals. A comparative histochemical study. Ann Med Exp Biol Fenn (1962) 0.77
Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res (2000) 2.35
Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer (1993) 2.15
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol (1988) 1.84
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med (1995) 1.66
Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun (1999) 1.58
Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). Cancer Res (1971) 1.57
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res (1994) 1.55
Similarities between early and delayed afterdepolarizations induced by isoproterenol in canine ventricular myocytes. Cardiovasc Res (1997) 1.51
Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol (1991) 1.47
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. J Clin Oncol (1995) 1.39
[Small cell lung cancer]. Ugeskr Laeger (1996) 1.39
Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol (1999) 1.37
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep (1972) 1.32
A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol (2006) 1.29
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res (1994) 1.28
Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer (1994) 1.22
Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol (2001) 1.21
Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med (1994) 1.20
Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol (1986) 1.19
Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. J Pharmacol Exp Ther (2000) 1.18
Bone-marrow examination in 100 consecutive patients with bronchogenic carcinoma. Lancet (1971) 1.18
Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis. Cancer Res (1982) 1.18
The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer (1988) 1.18
Scanning and radiology of the carpal scaphoid bone. Acta Orthop Scand (1979) 1.16
Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet (1987) 1.15
N-Acylethanolamines and precursor phospholipids - relation to cell injury. Chem Phys Lipids (2000) 1.15
Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes. Cancer (1980) 1.12
Lung cancer. Cancer Chemother Biol Response Modif (1991) 1.11
Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol (1989) 1.10
Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol (2005) 1.08
Activational role of cannabinoids on movement. Eur J Pharmacol (2000) 1.08
Non-small-cell lung cancer--stalemate or progress? N Engl J Med (2000) 1.08
Commentary: current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep (1982) 1.08
Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res (1997) 1.07
Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer (1974) 1.06
Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thromb Res (1994) 1.06
Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. Br J Cancer (1986) 1.05
Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res (1980) 1.05
Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. J Clin Oncol (1987) 1.05
Combination chemotherapy of advanced lung cancer: a randomized trial. Cancer (1976) 1.05
Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience (2002) 1.03
Multiple endocrine adenomatosis of mixed type. Acta Med Scand (1976) 1.02
Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev (1993) 1.02
The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer (1971) 1.01
Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol (1986) 1.00
Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung. Blood (1985) 0.99
Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res (1983) 0.98
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep (1985) 0.97
Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol (1996) 0.97
Early and delayed afterdepolarizations associated with cesium chloride-induced arrhythmias in the dog. J Cardiovasc Pharmacol (1990) 0.96
Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol (1991) 0.96
Bone marrow involvement in small cell anaplastic carcinoma of the lung: prognostic and therapeutic aspects. Cancer (1980) 0.95
The clinical and screening age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet (1989) 0.95
Intrinsically disordered proteins undergo and assist folding transitions in the proteome. Arch Biochem Biophys (2012) 0.94
Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: proposed role in neurotoxicity. Biochem Pharmacol (1998) 0.94
Cell kinetic studies in patients with small cell carcinoma of the lung. Cancer (1974) 0.94
Testicular carcinoma in Denmark 1976-1980. Stage and selected clinical parameters at presentation. Acta Radiol Oncol (1984) 0.94
Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. Ann Intern Med (1978) 0.93
Brain metastases from small cell lung cancer treated with combination chemotherapy. Eur J Cancer Clin Oncol (1988) 0.92
The cyto-centrifuge and cerebrospinal fluid cytology. Acta Cytol (1974) 0.92
The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol (1987) 0.91
Long-term survival in small cell carcinoma of the lung. JAMA (1980) 0.91
Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients. Eur J Cancer Clin Oncol (1986) 0.91
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer (1997) 0.91
Comparison of characteristics of human small cell carcinoma of the lung in patients, in vitro and transplanted into nude mice. Acta Pathol Microbiol Immunol Scand A (1986) 0.91
Ovariectomy and estrogen-induced alterations in myocardial contractility in female rabbits: role of the L-type calcium channel. J Pharmacol Exp Ther (1998) 0.91
Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial. J Natl Cancer Inst (1993) 0.91
Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. Br J Cancer (1999) 0.91
Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines. Eur J Cancer Clin Oncol (1987) 0.90
Pressure and blood flow in pituitary adenomas measured during transsphenoidal surgery. Br J Neurosurg (1992) 0.90
Intracranial metastases in small cell carcinoma of the lung: correlation of clinical and autopsy findings. Cancer (1982) 0.90
The incorporation of 67 Ga in normal and malignant cells and its dependence on growth rate. Br J Radiol (1972) 0.89
Genetic instability of cell lines derived from a single human small cell carcinoma of the lung. Eur J Cancer Clin Oncol (1985) 0.89
A clinical model for quality of life assessment in cancer patients receiving chemotherapy. Ann Oncol (2000) 0.89
Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol (1993) 0.89
Bone-marrow examination in the staging of small-cell anaplastic carcinoma of the lung with special reference to subtyping. An evaluation of 203 consecutive patients. Cancer (1977) 0.88
Staging of inoperable patients with bronchogenic carcinoma with special reference to bone marrow examination and peritoneoscopy. Cancer (1972) 0.88
Intensive combined chemotherapy and radiotherapy in patients with nonresectable bronchogenic carcinoma. Cancer (1972) 0.88
The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes. Radiology (1973) 0.88
Ectopic placental proteins in nontrophoblastic tumors. Serial measurements following chemotherapy. Cancer (1975) 0.87
Treatment of malignant germ cell tumors. Ann Oncol (1990) 0.87
SK3 K+ channel-deficient mice have enhanced dopamine and serotonin release and altered emotional behaviors. Genes Brain Behav (2008) 0.87
Calcitonin gene-related peptide and calcitonin in medullary thyroid carcinoma. Clin Endocrinol (Oxf) (1986) 0.87
Bilateral bone-marrow examinations in small-cell anaplastic carcinoma of the lung. Acta Pathol Microbiol Scand A (1979) 0.86
A phase I evaluation of N10-propargyl-5,8-dideazafolic acid. Eur J Cancer Clin Oncol (1988) 0.86
L-asparaginase toxicity. Cancer Res (1969) 0.86
Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemother Pharmacol (2004) 0.86
Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res (1998) 0.86
Coenzyme Q10 treatment in serious heart failure. Biofactors (1999) 0.86
Intracranial metastases in small cell carcinoma of the lung. Prognostic aspects. Cancer (1983) 0.85
The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay. Eur J Cancer Clin Oncol (1988) 0.85
Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res (1991) 0.85
Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer (1993) 0.85
Selective cognitive deficits and reduced hippocampal brain-derived neurotrophic factor mRNA expression in small-conductance calcium-activated K+ channel deficient mice. Neuroscience (2009) 0.85